The FDA may be withholding a final 180-day exclusivity decision for Mallinckrodt’s Concerta generic until an appeals court resolves a legal battle over Actos generics that could dictate what types of regulatory filings lead to an exclusivity reward, a legal expert says.
Washington Drug Letter